Literature DB >> 28064204

A histological positive margin after surgery is correlated with high local re-recurrence rate in patients with recurrent myxofibrosarcoma.

Kazutaka Kikuta1,2, Robert Nakayama1, Akihiko Yoshida3, Aya Sasaki4, Kaori Kameyama4, Hirokazu Chuman2, Akira Kawai2, Masaya Nakamura1, Morio Matsumoto1, Hideo Morioka1.   

Abstract

OBJECTIVE: Myxofibrosarcoma has high frequency of local recurrence after surgery. To determine an optimal treatment for recurrent tumors, clinical features of recurrent cases should be characterized.
METHODS: We performed a retrospective analysis of 30 patients with recurrent myxofibrosarcoma who underwent surgery between 1999 and 2008.
RESULTS: A negative margin after surgery was achieved in only 12 patients (40.0%). The 5-year re-recurrence free-survival rate was 31.7%. The 5-year re-recurrence free survival for those with positive histological margin and those with negative margin were 9.8% and 62.3%, respectively, which indicated that a positive margin was the significant predictor of poor prognosis (P = 0.006). In 21 patients with recurrent myxofibrosarcoma in the extremities, 10 patients (47.6%) ultimately underwent amputation in the follow-up period and the 5-year amputation-free survival rate was 62.5%. The 5-year metastasis-free survival rates and the 5-year overall survival rates were 84.8% and 83.6%, respectively.
CONCLUSIONS: In this study, the majority of recurrent cases could not achieve negative margins; notably, a positive margin is a significant poor prognostic indicator of local re-recurrence in patients with recurrent myxofibrosarcoma. To control local recurrence of myxofibrosarcoma was extremely difficult and amputation is often needed in the extremity cases.
© The Author 2017. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com

Entities:  

Keywords:  amputation; limb salvage; local recurrence; myxofibrosarcoma; surgical margin

Mesh:

Year:  2017        PMID: 28064204     DOI: 10.1093/jjco/hyw199

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  7 in total

1.  What Is the Success of Repeat Surgical Treatment of a Local Recurrence After Initial Wide Resection of Soft Tissue Sarcomas?

Authors:  Hideshi Sugiura; Satoshi Tsukushi; Masahiro Yoshida; Yoshihiro Nishida
Journal:  Clin Orthop Relat Res       Date:  2018-09       Impact factor: 4.176

2.  Remarkable response to anti-PD1 immunotherapy in refractory metastatic high-grade myxofibrosarcoma patient: A case report.

Authors:  Yi Luo; Li Min; Yong Zhou; Fan Tang; Minxun Lu; Hongmei Xie; Yitian Wang; Hong Duan; Wenli Zhang; Chongqi Tu
Journal:  Medicine (Baltimore)       Date:  2021-03-26       Impact factor: 1.817

3.  PROGNOSTIC FACTORS IN PATIENTS WITH APPENDICULAR MYXOFIBROSARCOMA.

Authors:  Juan Pablo Zumárraga; Felipe Augusto Ribeiro Batista; André Mathias Baptista; Marcelo Tadeu Caiero; Luis Pablo de la Rosa Martino; Olavo Pires de Camargo
Journal:  Acta Ortop Bras       Date:  2018       Impact factor: 0.513

4.  Tumor-Activatable Clinical Nanoprobe for Cancer Imaging.

Authors:  Derek Reichel; Manisha Tripathi; Pramod Butte; Rola Saouaf; J Manuel Perez
Journal:  Nanotheranostics       Date:  2019-05-04

5.  Oncological Outcomes in Patients with Appendicular Myxofibrosarcomas: A Retrospective Study.

Authors:  Yonghoon Lee; Michael P Guertin; Spencer Summers; Sheila A Conway; Mothasem Al Maaieh; Raphael Yechieli; Jonathan Trent; Andrew E Rosenberg; Juan Pretell-Mazzini
Journal:  J Oncol       Date:  2021-11-28       Impact factor: 4.375

6.  Recurrent neck myxofibrosarcoma: a case report.

Authors:  Chiara Pagnoni; Luca Improta; Rossana Alloni; Francesco Mallozzi Santa Maria; Irene Aprile; Beniamino Brunetti; Carlo Greco; Bruno Vincenzi; Alessandro Gronchi; Sergio Valeri
Journal:  J Med Case Rep       Date:  2021-10-01

Review 7.  The Extracellular Matrix in Soft Tissue Sarcomas: Pathobiology and Cellular Signalling.

Authors:  Valeriya Pankova; Khin Thway; Robin L Jones; Paul H Huang
Journal:  Front Cell Dev Biol       Date:  2021-12-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.